Filing Details

Accession Number:
0001209191-20-025983
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-28 17:07:46
Reporting Period:
2020-04-24
Accepted Time:
2020-04-28 17:07:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1796280 Oric Pharmaceuticals Inc. ORIC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1282930 L Carl Gordon C/O Orbimed Advisors, Llc
601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-04-24 281,250 $16.00 281,250 No 4 P Indirect See footnotes
Common Stock Acquisiton 2020-04-28 1,875,000 $0.00 2,156,250 No 4 C Indirect See footnotes
Common Stock Acquisiton 2020-04-28 373,356 $0.00 2,529,606 No 4 C Indirect See footnotes
Common Stock Acquisiton 2020-04-28 236,111 $0.00 2,765,717 No 4 C Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2020-04-28 1,875,000 $0.00 1,875,000 $0.00
Common Stock Series C Preferred Stock Disposition 2020-04-28 373,356 $0.00 373,356 $0.00
Common Stock Series D Preferred Stock Disposition 2020-04-28 236,111 $0.00 236,111 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The shares are held of record by by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
  2. Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.